A potential mechanism of a cationic cyclopeptide for enhancing insulin delivery across caco-2 cell monolayers

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 10, 2013, Pages 1602-1607

  Chang, Mingming ^a   Li, Xiaohui ^a   Sun, Yuming ^a   Cheng, Fang ^a   Li, Yueqing ^a   Zhao, Weijie ^a   Wang, Qing ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Cationic cyclopeptide; Endocytosis; Insulin; Paracellular delivery; Tight junction

Indexed keywords

ALANYLCYSTEINYLSERYLSERYLLYSYLLYSYLSERYLYSYLHISTIDYLCYSTEINYLGLYCINE; CLAUDIN 1; CYCLOPEPTIDE; PIG INSULIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG TRANSPORT; ELECTRIC RESISTANCE; IMMUNOFLUORESCENCE MICROSCOPY; MONOLAYER CULTURE; PROTEIN LOCALIZATION; TEMPERATURE SENSITIVITY; TRANSEPITHELIAL ELECTRIC RESISTANCE;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CATIONS; CELL MEMBRANE PERMEABILITY; CLAUDIN-1; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN; PEPTIDES, CYCLIC; TIGHT JUNCTION PROTEINS; TIGHT JUNCTIONS;

EID: 84887097062     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00487     Document Type: Article

References (32)

1. Maher S, Brayden DJ, Feighery L, McClean S. Cracking the junction: update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs. Crit. Rev. Ther. Drug Carrier Syst., 25, 117-168 (2008). (Pubitemid 351655039)
2. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P, European NanoBioPharmaceutics Research Initiative. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol., 87, 212-251 (2009).
3. Khafagy el S, Morishita M, Isowa K, Imai J, Takayama K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release, 133, 103-108 (2009).
4. Maher S, Devocelle M, Ryan S, McClean S, Brayden DJ. Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. Int. J. Pharm., 387, 154-160 (2010).
5. Chang M, Li X, Sun Y, Cheng F, Wang Q, Xie X, Zhao W, Tian X. Effect of cationic cyclopeptides on transdermal and transmembrane delivery of insulin. Mol. Pharm., 10, 951-957 (2013).
6. Kato K, Shirasaka Y, Kuraoka E, Kikuchi A, Iguchi M, Suzuki H, Shibasaki S, Kurosawa T, Tamai I. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol. Pharm., 7, 1747-1756 (2010).
7. Järver P, Langel U. Cell-penetrating peptides-a brief introduction. Biochim. Biophys. Acta, 1758, 260-263 (2006).
8. Zhu WL, Lan H, Park IS, Kim JI, Jin HZ, Hahm KS, Shin SY. Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. Biochem. Biophys. Res. Commun., 349, 769-774 (2006). (Pubitemid 44344580)
9. Kim YC, Ludovice PJ, Prausnitz MR. Transdermal delivery en-hanced by magainin pore-forming peptide. J. Control. Release, 122, 375-383 (2007). (Pubitemid 47404674)
10. Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc. Natl. Acad. Sci. U.S.A., 108, 15816-15821 (2011).
11. Chen S, Han K, Yang J, Lei Q, Zhuo RX, Zhang XZ. Bioreducible polypeptide containing cell-penetrating sequence for efficient gene delivery. Pharm. Res., 30, 1968-1978 (2013).
12. Fu A, Zhao Z, Gao F, Zhang M. Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells. Pharm. Res., 30, 2108-2117 (2013).
13. Wong V, Gumbiner BM. A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J. Cell Biol., 136, 399-409 (1997). (Pubitemid 27063089)
14. Tavelin S, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P. A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol., 64, 1530-1540 (2003). (Pubitemid 37532242)
15. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, Tsukita S. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol., 147, 195-204 (1999). (Pubitemid 30211807)
16. Wang G, Zabner J, Deering C, Launspach J, Shao J, Bodner M, Jolly DJ, Davidson BL, McCray PB Jr. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am. J. Respir. Cell Mol. Biol., 22, 129-138 (2000). (Pubitemid 30351473)
17. Hochman JH, Fix JA, LeCluyse EL. In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine. J. Pharmacol. Exp. Ther., 269, 813-822 (1994). (Pubitemid 24157356)
18. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet., 42, 1107-1128 (2003). (Pubitemid 37357648)
19. McEwan GT, Jepson MA, Hirst BH, Simmons NL. Polycationinduced enhancement of epithelial paracellular permeability is independent of tight junctional characteristics. Biochim. Biophys. Acta, 1148, 51-60 (1993). (Pubitemid 23146789)
20. Ohtake K, Natsume H, Ueda H, Morimoto Y. Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats. J. Control. Release, 82, 263-275 (2002). (Pubitemid 34880183)
21. Kondoh M, Yoshida T, Kakutani H, Yagi K. Targeting tight junction proteins-significance for drug development. Drug Discov. Today, 13, 180-186 (2008).
22. Wang XD, Meng MX, Gao LB, Liu T, Xu Q, Zeng S. Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int. J. Pharm., 378, 1-8 (2009).
23. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J. Control. Release, 140, 86-94 (2009).
24. Kawauchiya T, Takumi R, Kudo Y, Takamori A, Sasagawa T, Takahashi K, Kikuchi H. Correlation between the destruction of tight junction by patulin treatment and increase of phosphorylation of ZO-1 in Caco-2 human colon cancer cells. Toxicol. Lett., 205, 196-202 (2011).
25. Behrens I, Kissel T. Do cell culture conditions influence the carriermediated transport of peptides in Caco-2 cell monolayers? Eur. J. Pharm. Sci., 19, 433-442 (2003). (Pubitemid 36952405)
26. Yen W-C, Lee VHL. Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers. J. Control. Release, 36, 25-37 (1995).
27. Morita K, Miyachi Y. Tight junctions in the skin. J. Dermatol. Sci., 31, 81-89 (2003). (Pubitemid 36379058)
28. Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochim. Biophys. Acta, 1778, 631-645 (2008).
29. Xu LF, Teng X, Guo J, Sun M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. Inflammation, 35, 308-315 (2012).
30. Thanabalasundaram G, Pieper C, Lischper M, Galla HJ. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res., 1347, 1-10 (2010).
31. Li N, Lewis P, Samuelson D, Liboni K, Neu J. Glutamine regulates Caco-2 cell tight junction proteins. Am. J. Physiol. Gastrointest. Liver Physiol., 287, G726-G733 (2004). (Pubitemid 39096640)
32. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta, 1788, 892-910 (2009).